Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

892

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: GFF MDI (PT 003)
DRUG: GP MDI (PT001)
DRUG: FF MDI (PT005)
DRUG: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)

Sponsor

Pearl Therapeutics, Inc.